Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
Aranapakam M. Venkatesan, Rego Park, NY (US); Scott K. Thompson, Phoenixville, PA (US); Roger A. Smith, Chester Springs, PA (US); Sanjeeva P. Reddy, Chester Springs, PA (US); Raghava Reddy Kethiri, Bangalore (IN); Purushottam M. Dewang, Bangalore (IN); Gurulingappa Hallur, Bangalore (IN); and Chandrika Mulakala, Bangalore (IN)
Assigned to ASANA BIOSCIENCES, LLC, Bridgewater, NJ (US)
Filed by Asana Biosciences, LLC, Bridgeville, NJ (US)
Filed on Jul. 6, 2021, as Appl. No. 17/368,559.
Application 17/368,559 is a continuation of application No. 16/790,082, filed on Feb. 13, 2020, granted, now 11,103,491.
Application 16/790,082 is a continuation of application No. 15/183,504, filed on Jun. 15, 2016, granted, now 10,751,332, issued on Aug. 25, 2020.
Claims priority of provisional application 62/175,756, filed on Jun. 15, 2015.
Prior Publication US 2023/0051842 A1, Feb. 16, 2023
1. A method of inhibiting ERK1/2, the method comprising contacting ERK1/2 with a compound that is N-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide:
or a pharmaceutically acceptable salt or stereoisomer thereof.